Zydus Lifesciences receives USFDA approval for blood pressure tablets
The drug will be manufactured at the company's facility in Ahmedabad SEZ-II, India.
image for illustrative purpose
Zydus Lifesciences Ltd announced on Friday that it received tentative approval from the US health regulator to sell Azilsartan Medoxomil and Chlorthalidone tablets for treating high blood pressure.
The approval by the US Food and Drug Administration (USFDA) covers tablets in strengths of 40 mg/12.5 mg and 40 mg/25 mg, according to a regulatory filing by Zydus Lifesciences.
These tablets, combining Azilsartan and Chlorthalidone, are used to lower blood pressure. The drug will be manufactured at the company's facility in Ahmedabad SEZ-II, India.
In Friday's trading, Zydus Lifesciences Ltd saw a 1.54 percent increase in its shares, reaching Rs 1,107.25 today.
Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited, is an Indian pharmaceutical company that specializes in generic drugs.
Headquartered in Ahmedabad, it was ranked 100th in the Fortune India 500 list in 2020.
